紫龙金片维持治疗晚期非小细胞肺癌患者的疗效观察

发布时间：2018-10-24 17:50

【摘要】：目的观察同步放化疗后紫龙金片维持治疗对局部晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效及生活质量的影响。方法 66例经同步放化疗后取得缓解或稳定的局部晚期NSCLC患者,按随机数字表法分为治疗组和对照组,每组33例。治疗组给予紫龙金片(0.65 g/片),每次4片,每日3次,服药至疾病进展或无法耐受;对照组给予安慰剂,每次4片,每日3次。统计分析两组患者的无疾病进展生存期,1、2年生存率及生活质量的改变。结果试验过程中有4例脱落,62例可评价疗效,治疗组30例,对照组32例。治疗组和对照组的无进展生存期(progression free survival,PFS)分别为9.20个月、6.23个月,两组比较,差异有统计学意义(P0.05);1年生存率治疗组为73.0%,优于对照组的51.7%(P0.05);治疗组和对照组2年生存率分别为52.0%、48.6%,两组比较,差异无统计学意义(P0.05);与对照组比较,治疗组躯体、角色、社会功能领域及总健康状况得分升高,乏力、呼吸困难及咳嗽得分下降(P0.05),治疗组神疲乏力、少气懒言、头晕眼花、食欲不振、咳嗽、自汗症状改善(P0.05);两组患者的不良反应均在可接受范围内。结论紫龙金片维持治疗局部晚期NSCLC安全有效,可延长患者的无进展生存期及1年生存率,改善局部晚期NSCLC的中医症状,提高患者的生活质量。
[Abstract]:Objective to observe the effect of Zilongjin tablet maintenance therapy on local advanced non-small cell lung cancer (non-small cell lung cancer,NSCLC) after simultaneous radiotherapy and chemotherapy. Methods 66 patients with locally advanced NSCLC who had achieved remission or stability after simultaneous radiotherapy and chemotherapy were divided into treatment group (n = 33) and control group (n = 33). The treatment group was given Zilongjin tablet (0.65 g / tablet), 4 tablets per day, 3 times a day, until the disease progressed or intolerable, while the control group was given placebo, 4 tablets per day, 3 times a day. The progression-free survival time, 1-and 2-year survival rate and quality of life were statistically analyzed in both groups. Results there were 4 cases of shedding in the course of the experiment, 62 cases could be evaluated, 30 cases in the treatment group and 32 cases in the control group. The progressive survival time (progression free survival,PFS) of the treatment group and the control group were 9.20 months and 6.23 months, respectively. The 1-year survival rate in the treatment group was 73.0, which was higher than that in the control group (51.7%, P0.05); the 2-year survival rate in the treatment group and the control group was 52.0 and 48.6, respectively. There was no significant difference between the two groups (P0.05); compared with the control group, the body and role of the treatment group were significantly higher than that of the control group. The scores of social function field and general health state increased, fatigue, dyspnea and cough decreased (P0.05). The symptoms of self-sweating were improved (P0.05); the adverse reactions of both groups were within acceptable range. Conclusion Zilongjin tablet is safe and effective in the treatment of local advanced NSCLC. It can prolong the progression-free survival time and 1-year survival rate, improve the TCM symptoms of local advanced NSCLC and improve the quality of life of the patients.
【作者单位】：浙江省绍兴市人民医院放疗科;
【基金】：浙江省中医药科技计划资助项目(No.2012ZB160)
【分类号】：R734.2

【相似文献】